S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

Background: There is no clear consensus on second-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma (PDAC) after failure of first-line gemcitabine plus nab-paclitaxel (GnP). Objectives: This study aimed to compare the efficacy and safety of oxaliplatin plus S-1 (SOX) vers...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Hui Tang, Zhengxia Li, Tingting You, Jinrong Ying, Mingming Yuan, Yuejuan Cheng, Yingyi Wang, Huanwen Wu, Chunmei Bai
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2025-09-01
Serier:	Therapeutic Advances in Medical Oncology
Online adgang:	https://doi.org/10.1177/17588359251378698
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!